Exscientia Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Exscientia's earnings have been declining at an average annual rate of -44.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 4% per year.
Belangrijke informatie
-44.5%
Groei van de winst
-19.3%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -4.0% |
Rendement op eigen vermogen | -43.8% |
Nettomarge | -616.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Opbrengsten en kosten
Hoe Exscientia geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 21 | -130 | 43 | 111 |
31 Mar 24 | 20 | -129 | 38 | 119 |
31 Dec 23 | 20 | -146 | 45 | 128 |
30 Sep 23 | 24 | -144 | 42 | 135 |
30 Jun 23 | 22 | -148 | 41 | 139 |
31 Mar 23 | 26 | -141 | 42 | 139 |
31 Dec 22 | 27 | -119 | 38 | 129 |
30 Sep 22 | 25 | -100 | 35 | 112 |
30 Jun 22 | 36 | -69 | 34 | 88 |
31 Mar 22 | 29 | -59 | 29 | 63 |
31 Dec 21 | 27 | -49 | 26 | 44 |
30 Sep 21 | 27 | -36 | 21 | 29 |
30 Jun 21 | 10 | -39 | 14 | 19 |
31 Mar 21 | 13 | -24 | 8 | 13 |
31 Dec 20 | 10 | -22 | 6 | 11 |
31 Dec 19 | 9 | -6 | 5 | 7 |
Kwaliteitswinsten: EXAI is currently unprofitable.
Groeiende winstmarge: EXAI is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EXAI is unprofitable, and losses have increased over the past 5 years at a rate of 44.5% per year.
Versnelling van de groei: Unable to compare EXAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: EXAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: EXAI has a negative Return on Equity (-43.78%), as it is currently unprofitable.